National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Benralizumab (Fasenra®) Autoinjector under High Tech Drug Arrangements.

Benralizumab (Fasenra®) is indicated for use as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

 

NCPE Assessment Process Complete
Rapid review commissioned 31/03/2020
Rapid review completed 28/04/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that benralizumab not be considered for reimbursement under high tech drug arrangements at the submitted price*.

 

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.